2,5-Dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]-4-pyrimidinamine

CAS : 761440-16-8

Ref. 3D-FD75047

Informations sur le produit

• Nom: 2,5-Dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]-4-pyrimidinamine
• Synonymes: (2,5-Dichloropyrimidin-4-yl)[2-[(propan-2-yl)sulfonyl]phenyl]amine, 4-Pyrimidinamine, 2,5-dichloro-N-[2-[(1-methylethyl)sulfonyl]phenyl]-, (2,5-Dichloropyrimidin-4-yl)[2-(propane-2-sulfonyl)phenyl]-amine, 2,5-Dichloro-N-[2-(propane-1-sulfonyl)phenyl]pyrimidin-4-amine, (2,5-Dichloro-pyrimidin-4-yl)-[2-(propane-1-sulfony)-phenyl]-amine, 2,5-Dichloro-N-(2-(iso-propylsulfonyl)phenyl)-pyrimidin-4-amine, 2,5-dichloro-N-(2-(isopropyl sulfonyl)phenyl)-pyrimidine-4-amine, 2,5-Dichloro-N-(2-(isopropylsulfonyl)-phenyl)pyrimidin-4-amine, 2,5-Dichloro-N-[2-(isopropylsulfonyl)phenyl]pyrimidin-4-amine

Description

Ceritinib is a small molecule that inhibits the activity of tyrosine kinases, including c-Kit and PDGFR. It has been shown to have potent in vitro activity against a broad range of solid tumours and has been approved by the US FDA for use in patients with non-small cell lung cancer (NSCLC) who have progressed following at least one platinum-based chemotherapy regimen.

Ceritinib binds to c-Kit and PDGFR and inhibits their ability to phosphorylate downstream targets, which prevents many cellular processes from occurring. Ceritinib also inhibits the proliferation of tumour cells by interfering with their ability to form new blood vessels. This drug can be used as an adjuvant treatment for NSCLC after at least one platinum-based chemotherapy regimen.

• Marque: Biosynth

Propriétés chimiques

• Masse moléculaire: 346.23 g/mol
• Formule: C₁₃H₁₃Cl₂N₃O₂S
• Degré de pureté: Min. 95%